NEW YORK (GenomeWeb News) – Epigenomics and Wuhan Kindstar Clinical Diagnostics today announced a licensing and supply deal for the Epi proLung tissue assay for the Chinese market.

The terms of the deal call for Kindstar to commercialize Epigenomics' assay, while the Berlin-based company will manufacture and supply it. Epigenomics also will provide support "with respect to medical and regulatory considerations."

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.